8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-10-06 AccNo: 0001140361-26-038728 Size: 187 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PDS Biotechnology shares are trading higher after the company announced the publication of Phase 2 trial results for PDS0101 in combination with pembrolizumab in JAMA Oncology.
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for